Survival Outcomes of Patients Treated with Hypofractionated Stereotactic Body Radiation Therapy for Parotid Gland Tumors: a Retrospective Analysis by Sana D. Karam et al.
ORIGINAL RESEARCH ARTICLE
published: 31 May 2012
doi: 10.3389/fonc.2012.00055
Survival outcomes of patients treated with
hypofractionated stereotactic body radiation therapy for
parotid gland tumors: a retrospective analysis
Sana D. Karam1*, JamesW. Snider 1, HongkunWang2, MargauxWooster 1, Christopher Lominska3,
John Deeken4, Kenneth Newkirk 5, Bruce Davidson5 and K.William Harter 1
1 Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, USA
2 Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University Hospital, Washington, DC, USA
3 Department of Radiation Oncology, The University of Kansas, Kansas City, KS, USA
4 Department of Hematology/Oncology, Georgetown University Hospital, Washington, DC, USA
5 Department of Otolaryngology, Georgetown University Hospital, Washington, DC, USA
Edited by:
Silvia C. Formenti, NewYork
University Langone Medical Center,
USA
Reviewed by:
Peter B. Schiff, NYU School of
Medicine, USA
Joshua Silverman, NewYork
University Medical Center, USA
Kevin Du, NYU Medical Center, USA
*Correspondence:
Sana D. Karam, Department of
Radiation Medicine, Georgetown
University Hospital, 3800 Reservoir
Road, NW,Washington, DC 20007,
USA.
e-mail: sana.d.karam@gunet.
georgetown.edu
Background: to review a single-institution experience with the management of parotid
malignancies treated by fractionated stereotactic body radiosurgery (SBRT). Findings:
Between 2003 and 2011, 13 patients diagnosed with parotid malignancies were treated
with adjuvant or deﬁnitive SBRT to a median dose of 33Gy (range 25–40Gy). There were
11 male and two female patients with a median age of 80. Ten patients declined conven-
tional radiation treatment and three patients had received prior unrelated radiation therapy
to neighboring structures with unavailable radiation records. Six patients were treated with
deﬁnitive intent while seven patients were treated adjuvantly for adverse surgical or patho-
logic features. Five patients had clinical or pathologic evidence of lymph node disease.
Conclusion: at a median follow-up of 14months only one patient failed locally, and four
failed distantly. The actuarial 2-year overall survival, progression-free survival, and local-
regional control rates were 46, 84, and 47%, respectively. Statistical analysis revealed
surgery as a positive predictor of overall survival while presence of gross disease was a
negatively correlated factor (p< 0.05).
Keywords: parotid malignancies, stereotactic radiosurgery, toxicity
INTRODUCTION
Salivary gland cancers are rare, comprising only 3–5% of all head
and neck cancers, with the majority localized to the parotid gland
(Guzzo et al., 2010). Histologically, these tumors are very diverse
with varying natural history (Guzzo et al., 2010). Surgery has
historically been the mainstay of treatment for parotid malignan-
cies (Spiro et al., 1973). In high grade tumors, advanced stage
(T3/4), and/or adverse pathologic features, adjuvant postopera-
tive radiation treatment (RT) has been shown to provide superior
outcomes to surgery alone (Garden et al., 1994; Sakata et al., 1994;
Mendenhall et al., 2005; Chen et al., 2007). In patients whom
are considered surgically inoperable, who present with incom-
pletely resected tumors, or who refuse surgery out of personal
preference, primary RT alone is the treatment modality of choice,
with reported 5-year local control rates of 55–70% (Mendenhall
et al., 2005; Chen et al., 2006). However, the protracted course
of conventional RT is a deterrent to some patients, especially the
elderly, who have other medical co-morbidities. Additionally, in
patients with prior unrelated irradiation that has exposed adjacent
critical structures to previous radiation, concern about exceeding
tolerance to those areas presents a major challenge to delivering
adequate dosage to the salivary glands using the conventional RT
approach.
Stereotactic radiosurgery (SBRT) represents an appealing
option for the management of salivary gland tumors either as
a means of dose escalation or for avoiding adjacent critical struc-
tures that have been previously exposed to RT. The convenience
of administering the treatment over a course of 5 days is also
very appealing to those who perceive the prolonged treatment
course of the conventional approach as a major challenge to
treatment delivery. SBRT uses multiple convergent beams with
various targeting techniques to deliver highly conformal therapy
in an accurate manner. Gamma Knife-based SBRT technolo-
gies, which require external frame-based ﬁxation devices, have
been previously used in the treatment of salivary malignancies
with skull base invasion, with local control rates at 40months
of 82% (Douglas et al., 2008). Successful use of SBRT has also
been reported for recurrent pleomorphic adenoma with skull
base invasion (Kamida et al., 2005). The CyberKnife SBRT sys-
tem (Accuray, Inc., Sunnyvale, CA, USA) allows conformal treat-
ment of sites throughout the head and neck region. This sys-
tem uses real-time image guidance for targeting without rigid
external ﬁxation (Dieterich and Pawlicki, 2008; Dieterich and
Gibbs, 2011). Multiple treatment sessions can be used, poten-
tially reducing late normal tissue toxicity via dose fractionation.
We report our institutional experience with fractionated SBRT
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irradiation of salivary gland tumors, addressing feasibility, safety,
and outcomes.
PATIENTS AND METHODS
PATIENTS
All patients diagnosed with parotid gland tumors and treated with
SBRT either in the deﬁnitive or adjuvant setting at our institu-
tion between September 2003 and March 2011 were included
in this analysis. There were no pre-existing eligibility criteria or
exclusion criteria. The group consisted of 13 patients diagnosed
with parotid gland tumors who either were not candidates for
deﬁnitive resection or who had undergone limited procedures
with gross or pathologically adverse features. Patients who refused
surgery and/or the more protracted course with conventional RT
were also included. Three patients had received prior unrelated
radiation therapy elsewhere, and their previous radiation records
were unavailable. The data were reviewed under an institutional
review board-approved retrospective protocol. Prior to treatment,
patients’caseswere discussed at the institutional,multidisciplinary
head and neck tumor board. Only one patient received radiosensi-
tizing chemotherapy, using carboplatin, which was given in three
cycles over a course of 3 weeks, before, during, and following SBRT.
FRACTIONATED STEREOTACTIC BODY RADIATION TREATMENT
The CyberKnife SBRT system (Accuray, Inc., Sunnyvale, CA) uses
a 6-MV X-band linear accelerator mounted on a fully artic-
ulated robotic arm. During treatment, two orthogonally posi-
tioned x-ray detectors provide real-time imaging of bony anatomy,
allowing for intrafraction movement correction. Treatment was
generally administered on an outpatient basis with each treat-
ment lasting approximately 45–90min. Most of the patients
received their treatments over the course of 7 days, consecu-
tive with the exception of holidays or weekends. Patients were
immobilized in the supine position with an Aquaplast facemask
(WRF/Aquaplast Corp., Wyckoff, NJ, USA). All patients under-
went a treatment planning computed tomography (CT) scan,
fused with a ﬂuorodeoxyglucose-positron emission tomography
(FDGPET/CT) scan with 1.0mm-thick slices. In all cases, mag-
netic resonance imaging (MRI) scanswith volumetric interpolated
breath-hold examination (VIBE) sequence and 1mm slices were
also used in planning. The MRI and PET images were then fused
with that of the simulation CT scan for treatment planning. The
gross tumor volume (GTV) was reconstructed based on the infor-
mation obtained from both the PET and the MRI together. The
PET-GTV was usually contoured to the halo, which is observed
around areas of maximal SUV uptake, as described by Ashamalla
et al. (2007). The sum of both the PET-contoured volume and
the MRI-contoured volume deﬁned the GTV. Once the GTV was
contoured, an expansion was done ranging from 2 to 10mm
depending on the pathologic margins status and proximity to crit-
ical structures to deﬁne the clinical tumor volume (CTV). Since
the threshold for treatment interruption by the Cyberknife deliv-
ery system is on the order of 1mm, no additional margin was
added for the planning target volume (PTV). In postoperative
cases the preoperative MRI was also fused with the postoperative
PET and MRI, and the sum of all volumes deﬁned the postop-
erative PTV. In patients who underwent surgical resection, the
PTV encompassed the entire surgical bed when feasible. The skull
base was electively included in the CTV for treatment of the
patient with adenoid cystic histology. In six cases, adjacent soft
tissue and immediate draining lymph nodes were targeted as a
separate PTV. For delineation of lymph node volumes, the same
anatomic landmarks as standard neck levels treated with conven-
tional fractionationwere used. For benign tumors or for low-grade
malignancies that were pathologically or radiographically node
negative, lymph nodes were not deliberately included. For high
grade malignancies, ipsilateral draining LN stations at risk for
microscopic diseasewere included. Themedian radiation dosewas
33Gy, but varied between 25 and 40Gy. Median dose per fraction
was 6Gy and varied between 5 and 8Gy. For neck irradiation, ipsi-
lateral neck irradiationwas given as 5 fractions,7 Gy each for a total
dose of 35Gy. Inverse planning was used to determine the dose to
the target volume while minimizing the dose to normal tissue.
All planning was completed within 1 week of imaging and typi-
cally patients initiated treatment within 2–3 weeks after imaging
depending on chemotherapy coordination. Treatment was gen-
erally completed within 7 days of initiation, consecutive with the
exception of holidays or weekends.
POST-TREATMENT FOLLOW-UP
Patients typically underwent a post-treatment surveillance with an
MRI scan 3months after the completion of SBRT and then every
6months thereafter (with an FDG PET/CT scan and MRI). Radi-
ographic imagingwas done on follow-up tomonitor disease recur-
rence locally, regionally, or distantly. For those with gross disease,
PET andMRIwere used tomonitor“response”to treatment as well
as regional and distant metastases. For those without evidence of
gross disease on treatment initiation, radiographic evaluation was
performed to monitor for disease recurrence locally, regionally, or
distantly. Clinical examinationwas conducted at the same interval,
with biopsy as indicated. Acute and late toxicity were graded using
the Radiation Therapy Oncology Group (RTOG) scoring criteria.
STATISTICAL ANALYSIS
Progression-free survival (PFS) was deﬁned as the time from the
ﬁrst day of SBRT treatment to local/distant failure or last follow-
up in living patients without evidence of recurrence/progression.
Locoregional control (LRC)wasdeﬁned similarly except that death
and distant failure were not considered events. Patients were cen-
sored at the time of death. Overall survival (OS) was the time
from SBRT treatment until death or last follow-up. Interpretation
of available FDGPET/CT,MRI, and CT scans with correlative clin-
ical examinations were used to assess for response of the treated
lesion 3months after SBRT. Complete response was deﬁned as
no evidence of disease in the treatment volume by both radi-
ographic and direct clinical examination. No response was deﬁned
as absence of marked change or increase in the treated lesion. Par-
tial response was deﬁned as not meeting the criteria for complete
response or no response. Log rank tests were used to evaluate the
association between clinical factors and survival outcomes. The
independent variables consideredwere surgery (yes,no),nodal sta-
tus (yes, no), presence or absence of gross disease (yes, no), SBRT
dose (<35Gy, ≥35Gy), grade (low, medium, high), nodal stage
per the AJCC staging system, age in years, size in centimeters, and
SBRT dose in Gy. The presence of positive margins was coded as
absence of gross disease, since most patients had one or the other.
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Kaplan–Meier plots are presented for selected signiﬁcant factors.
For long-term toxicity analyses, dysphagia (present, absent), ﬁbro-
sis (present absent), and soft tissue or bone radionecrosis (present,
absent) were the dependent variables. Analyses were performed in
SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).
RESULTS
PATIENT CHARACTERISTICS AND DISEASE PRESENTATION
Patient characteristics and treatment results are shown in Table 1.
The median age was 80 years (range 34–99 years). Eleven patients
weremale and patients presentedwith variable histology (Table 1).
Five patients had nodal involvement. A total of seven patients
had undergone maximal surgical resection prior to starting SBRT,
while six were treated with deﬁnitive SBRT. All patients that
received adjuvant SBRT had adverse features requiring the addi-
tion of postoperative radiation including positive margins, per-
ineural invasion, and extracapsular extension (Table 1). The rea-
sons for choosing SBRTover conventional external beam radiation
therapy (EBRT) included patient preference in 10 cases and prior
irradiation to adjacent critical structures in the other 3 (Table 1).
None of the patients had received previous radiation to the tumor
bed. The median dose was 33Gy but varied between 25 and 40Gy.
Similarly, the median dose per fraction varied between 5 and 8Gy.
Only one patient received chemotherapy.
PATTERNS OF FAILURE
Themedian follow-up was 14months (range 0–59months) for all
patients and 24months (range 3–59) for surviving patients. Pat-
terns of failure in relation to disease presentation for each patient
are summarized in Table 1. Only one patient failed locally, while
four failed distantly. One of the patients (#4, Table 1) had ini-
tially presented with solitary metastatic adenocarcinoma to the
C7 vertebral body of unknown primary that was treated with con-
ventional EBRT prior to presentation to our clinic. At the time
of treatment, he had no evidence of other metastatic disease and
had declined surgical treatment to the parotid bed. Three months
following SBRT treatment, he was diagnosed with widespread
metastatic disease to the thoracic vertebrae, rib cage, and liver.
He was treated with systemic chemotherapy but succumbed to
the disease 5months following treatment. However, he remained
without evidence of locoregional recurrence on imaging studies
performed 2weeks prior to his death.
CLINICAL OUTCOMES AND PROGNOSTICATORS
Clinical outcomes are summarized in Table 2 and Figures 1–3.
Correlations with patient presentation can be seen in Table 1.
The median OS and PFS were 20 and18months, respectively
(Figures 1–3;Table 2). Since only onepatient failed locally,median
local failure was not reportable in this series. Two-year actuarial
OS, LRC, and PFS were 46, 84, and 47%, respectively. A total of
seven patients died, but only four patients died of disease pro-
gression, locally or distantly. One patient died on treatment from
complications related to aspiration pneumonia. The others died
of complications unrelated to their disease. On univariate analysis,
gross disease was adversely correlated with OS (p = 0.01). Surgery,
on the other hand,was a positive predictor of OS (p = 0.01). There
were no other statistically signiﬁcant correlates of OS or PFS. Since
there was only one local failure, local control was excluded from
these analyses.
TOXICITY
Generally, the treatment was well tolerated. Six patients experi-
enced low-grade dysphagia 1week following the administration
of the treatment. The dysphagia was usually palliated by the use of
prescribedmouthwashornarcotics,but inno case did it require the
placement of a feeding tube. Fibrosis and trismus was noted in one
patient (#6, Table 1) and was treated with physical therapy. One
patient died on treatment (#11, Table 1) 6 days after the initiation
of SBRT, having received a total of 3 fractions of 7Gy each. The
cause of death was attributed to sepsis that developed secondary to
aspiration pneumonia. He did report dysphagia during the treat-
ment, but it was unclear if that led to the aspiration pneumonia.
One patient developed chronic ipsilateral otalgia without evidence
of pathology on clinical exam. None of the patients developed soft
tissue or bone necrosis.
DISCUSSION
The present study described our recent experience with the treat-
ment of parotid gland tumors using fractionated SBRT. The stan-
dard of care for salivary gland malignancies is surgery alone or
resection followed by postoperative RT for patients with advanced
pathological features (Fu et al., 1977). RT alone has been used,with
relatively good response rates, for select patients with unfavorable
prognosis who are poor surgical candidates. Conventionally, adju-
vant fractionated RT is most commonly delivered to a dose of
66–74Gy in 2Gy fractions. Reported LRC rates for such treatment
is on the order of 55–70% at 5 years (Mendenhall et al., 2005;
Chen et al., 2006). Advanced T stage disease and radiation doses
lower than 66Gy serve as predictors of local recurrence (Menden-
hall et al., 2005; Chen et al., 2006), contrary to the notion that
salivary tumors represent a radioresistant group of tumors. How-
ever, the duration of conventionally fractionated RT (42–62 days)
to represents a signiﬁcant burden for many patients, especially the
elderly. Even for patients willing to undergo conventionally frac-
tionatedRT,previous radiation to adjacent structuresmayprohibit
the delivery of adequate doses required to control gross disease.
Finally, conventional irradiation in the setting of gross disease has
demonstrated poor disease control rates,with long-termLRC rates
ranging from 20 to 30% in most reported studies (Laramore et al.,
1993). To our knowledge, this is the ﬁrst report of using SBRT for
the primary (deﬁnitive or adjuvant) treatment of parotid tumors
not involving the skull base.
Although these data represent a limited follow-up period, they
demonstrate favorable treatment response rates for SBRT that are
comparable to those reported in the literature using various RT
approaches. Five-year local control rates have been reported as
100, 59, and 55–70%, using hyperfractionated photon RT (Wang
and Goodman, 1991), neutron RT (Douglas et al., 2003), and con-
ventionally fractionated photonRT (Mendenhall et al., 2005; Chen
et al., 2006).With amedian follow-up of 14months (24 for surviv-
ing patients), our local control rate is 92%with an actuarial rate of
84% at 2 years. Differences in selection criteria, histological sub-
types, and treatment modality most likely account for the discrep-
ancies between observed outcomes across institutions. A trial with
direct comparison between the modalities is unlikely to accrue
given the relative rarity of this disease. The only randomized trial
for salivary gland carcinomas compared primary conventional
RT with photons to primary neutron therapy (Laramore et al.,
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Table 2 | Crude survival outcomes.
Median follow-up all patients (range) 14months (0–59)
Median follow-up surviving patients (range) 24months (3–59)
Median OS 20months
Median LRC Not reached
Median PFS 18months
Local failure (%) 1/13 (7.7%)
Distant failure (%) 4/13 (30.8%)
Any progression (%) 5/13 (38.5%)
Cancer-speciﬁc mortality (%) 4/13 (30.8%)
Overall mortality (%) 7/13 (53.8%)
2-Year actuarial overall survival 0.46 (0.30–0.75)
2-Year actuarial locoregional control 0.84 (0.68–0.98)
2-Year actuarial progression-free survival 0.47 (0.47–0.81)
FIGURE 1 | Overall survival for patients with parotid tumors treated
with SBRT. One patient died on treatment at time 0, so 12 patients are
represented. SBRT= stereotactic body radiation treatment.
1993). Performed by the RTOG and theMedical Research Council
(MRC), this study demonstrated the superiority of neutron ther-
apy (Laramore et al., 1993). The trial was, however, biased by the
uneven small number of patients, and the disproportionate distri-
bution of important prognosticators such as histology, tumors
size, nodal involvement, presence of disease recurrence, and
subtherapeutic doses of photon therapy (Laramore et al., 1993).
The OS rate reported in the current study of 46% at 2 years
is lower than what has been reported in the literature, but the
cancer-speciﬁc mortality of 36% is comparable to published
reports (Mendenhall et al., 2005). This is likely attributable to
the sample’s bias toward older patients with multiple cormorbid
medical conditions. Our series also demonstrated higher distant
failure rates than those previously reported in the primary set-
ting (Mendenhall et al., 2005; Chen et al., 2006, 2007). Recent
reports have demonstrated the beneﬁt of administering con-
current and/or adjuvant chemotherapy in patients with salivary
gland malignancies (Argiris et al., 2003; Salama et al., 2006; Tan-
vetyanon et al., 2009; Pederson et al., 2011; Schoenfeld et al., 2012).
Only one patient in our series who had presented with solitary
FIGURE 2 | Locoregional control for patients with parotid tumors
treated with SBRT. One patient died on treatment at time 0, so 12 patients
are represented. SBRT= stereotactic body radiation treatment.
FIGURE 3 | Progression-free survival for patients with parotid tumors
with SBRT. One patient died on treatment at time 0, so 12 patients are
represented. SBRT= stereotactic body radiation treatment.
metastases received chemotherapy, but other eligible candidates
for chemotherapy refused treatment.
Consistent with the published data, our results show a posi-
tive predictive correlation between surgery and OS (North et al.,
1990; Garden et al., 1994; Mendenhall et al., 2005; Chen et al.,
2006, 2007). Similarly the presence of gross disease represented
a negative predictor of OS. Our results are limited by the small
sample size. The observed differences could be due to selection
biases, given that patients referred for primary treatment with RT
are considered inoperable, have worse performance status, are less
rigorously staged, and are of more advanced age with multiple
medical co-morbidities.
Although there was no correlation between dose and survival
outcomes in our current series, we have generally adopted doses
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of 30–35Gy to control microscopic disease and 35–40Gy for gross
disease based on previous experience (Unger et al., 2010). The
toxicity from the treatment appears minimal, and the therapy is
generally well tolerated. However, one patient died of aspiration
pneumonia having experienced treatment-related dysphagia. It is
conceivable that this could have resulted from treatment. Addi-
tionally, three out of the four patients who died did so within
5months from the completion of therapy. As such, there may have
been insufﬁcient time to develop complications.
CONCLUSION
This study has demonstrated the possibility of using fraction-
ated SBRT for the treatment of parotid tumors in both the
deﬁnitive or adjuvant setting, for patients who refuse or are
poor candidates for conventional RT. Although at early follow-
up, treatment was generally well tolerated and without signiﬁ-
cant toxicity, long-term toxicity could not be evaluated in this
population given the small sample size of the study with an
actuarial 2 year survival of 45%. Our retrospective review is
limited by potential selection bias, small sample size, a hetero-
geneous population, varied tumor characteristics, and contrast-
ing treatment parameters. Future studies with increased sam-
ple size, longer follow-up, and less histological variability are
warranted.
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